HOME >> BIOLOGY >> NEWS
Idun develops new drug screen for treatments of stroke, heart attack, and cancer

Key apoptosis reaction adaptable to high throughput screening

KEYSTONE, Colorado, January 22, 2001 - Idun Pharmaceuticals, Inc. described the successful recreation in the lab of a key biological reaction that occurs in human cells and is part of the apoptosis pathway. This assay is being used to help understand the mechanism of apoptosis at the molecular level and to screen new drugs that modulate apoptosis. This development was presented at the Molecular Mechanisms of Apoptosis Meeting in Keystone, Colorado.

In the study, entitled, Reconstitution of Apaf-4/Procaspase-9 Holoenzyme-Mediated Procaspase-3 Activation: Requirement for Caspase-9 Conformational Change or Apaf-1 Association, it was shown that recombinant components of the human apoptosis pathway can be combined in vitro to carry out the activation of one of the key components that triggers programmed cell death.

Developing a key apoptosis reaction in vitro that mimics a natural in vivo reaction has important applications, both for use as a drug screen and as a tool to better understand how apoptosis is regulated, said Dr. Kevin Tomaselli, Vice President, Discovery Research and Co-Founder of Idun Pharmaceuticals. This gives us the ability to screen for drugs in a high throughput format that modulate apoptosis by affecting this specific apoptosis reaction.

Iduns expertise and success in apoptosis encompasses the entire breadth of cutting edge biotechnology, said Steven Mento, Ph.D., President and CEO of Idun Pharmaceuticals. We bring together the disciplines of gene discovery, functional genomics, high throughput screening (HTS), biochemical validation, structural modeling, and targeted drug development and apply them to the discovery and characterization of human apoptosis genes. This includes determining the function of the genes and their role in disease. Based on that, we develop new drugs to treat important human diseases such as cancer, heart attacks and stroke. N
'"/>

Contact: Lora Pike
l.pike@noonanrusso.com
415-677-4455 ext.211
Noonan/Russo Communications
21-Jan-2001


Page: 1 2

Related biology news :

1. Carnegie Mellon neuroscientist develops tool to image brain function at the cellular level
2. Carnegie Mellon U. develops microgel to recover enzymes for manufacturing, research assays
3. Scientists findings may lead to better understanding of how that sleep develops, matures
4. Fox Chase Cancer Center researcher develops new model for studying prions mad cow disease
5. US develops lethal new viruses
6. Brookhaven Lab develops ThraxVac to clean up anthrax
7. Carnegie Mellon develops new process for growing bone
8. Cancer could be caught before it develops
9. St. Jude develops vaccine against potential pandemic influenza virus H5N1 using reverse genetics
10. University of Ulster develops DNA fingerprint techniques to fight bio-terrorism
11. Clothing from Corn: DuPont develops innovative process to create polymer from renewable resources

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
Breaking Biology Technology:
Cached News: